
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suppository containing nitrofurazone, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No finished nitrofurazone product of any kind is listed; the directory holds only bulk ingredient records for it.
Suppository bases differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Nitrofurazone is a nitrofuran antibacterial for use on the skin that a pharmacy may compound when a prescriber orders it.
Nitrofurazone is a topical antibacterial of the nitrofuran group. It acts by killing bacteria or preventing their growth. In the United States it was sold by prescription as Furacin cream, soluble dressing and topical solution, and as generic ointments and solutions; an archived MedlinePlus page describes its use to treat infected burns and skin infections related to skin grafts. FDA's Drugs@FDA database lists every human nitrofurazone product as discontinued. The only current DailyMed listings are aquarium fish treatments filed as unapproved drugs and bulk powders, one labeled for animal drug compounding. There is therefore no FDA-approved human nitrofurazone product on the market. A prescriber might order nitrofurazone compounded for a patient because no manufactured human product exists. Compounded preparations are not FDA-approved and require a prescription.
No current FDA label exists for a human nitrofurazone product, so there is no boxed warning. The archived MedlinePlus page says to tell your prescriber about any past allergic reaction to nitrofurazone or to preservatives or dyes, and to report itching, rash or swelling, the side effects it lists. Some older solution and dressing forms contained polyethylene glycols, which can be absorbed through the skin and build up in people with kidney problems. In long-term feeding studies, the National Toxicology Program found clear evidence that nitrofurazone caused cancer in female rats and female mice. FDA prohibits its extralabel use in food-producing animals. It has not been studied in pregnant women; high oral doses in rabbits slightly increased stillbirths. It is not known whether it passes into breast milk. If the infection does not improve or gets worse, talk to your prescriber or pharmacist.
Nitrofurazone is a nitrofuran antibacterial applied topically; the archived MedlinePlus (USP DI) monograph describes bactericidal or bacteriostatic activity without further mechanistic detail, and no pharmacokinetic data were found in the sources reviewed. Historical labeled use: Furacin cream, soluble dressing and topical solution were prescription products for infected burns, with the cream and dressing also used for skin infections related to skin grafts. Drugs@FDA lists eleven human applications, NDA005795 (Furacin ointment), NDA017343 (Actin-N dressing) and nine ANDAs, all discontinued, all for topical use. No current human indication exists, so any compounded use is not an FDA-approved indication. NTP Technical Report 337 (1988) found clear evidence of carcinogenic activity in female F344/N rats and female B6C3F1 mice, equivocal evidence in male rats and no evidence in male mice in two-year feed studies. 21 CFR 530.41 lists nitrofurazone among drugs prohibited for extralabel use in food-producing animals. Polyethylene glycol bases warrant caution in renal impairment. Monitor for local hypersensitivity, and reassess if the wound does not improve. Nitrofurazone is not listed as a controlled substance in these sources. Dosing is per prescriber.
Wash your hands. If the suppository is soft, chill it in its wrapper in the refrigerator or under cool water for a few minutes, then unwrap it. For rectal use, coat the tip with a water-soluble lubricant (not petroleum jelly), lie on your side with your upper knee bent, and insert it pointed end first past the muscle at the opening. For vaginal use, lie on your back with knees bent and insert it as far as it comfortably goes, by finger or applicator; bedtime use limits leakage, and a panty liner protects clothing. Stay lying down about 15 minutes. Wash your hands.
Suppositories are nonaqueous, so under USP <795> they can carry a beyond-use date of up to 180 days at controlled room temperature or in the refrigerator when no other stability data apply. Storage depends on the base: fatty bases can soften at room temperature and may be labeled for the refrigerator, while polyethylene glycol bases usually do not need refrigeration. Keep them cool so they do not melt, and refrigerate them if your label says to.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Insert 1 unwrapped suppository